Site intended for healthcare professionals only
The pro-inflammatory activities of the calgranulins and HMGB1 can be counteracted by sRAGE the soluble form of their shared receptor. To understand the role of these molecules in AAV and […]
» Read moreWe recently recorded a high prevalence of inclusion body myositis (IBM) in patients with Sjögren’s syndrome (SS). Whether myositis patients with SS differ from myositis patients without SS in terms […]
» Read moreWe aimed to analyze the prevalence of non-criteria anti-phospholipid (aPL) antibodies and their role in the diagnosis, treatment and prognosis in a cohort of patients with clinical features consistent with […]
» Read moreAn important but often insufficient aspect of care in people with inflammatory arthritis (IA) is empowering patients to acquire a good understanding of their disease and building their ability to […]
» Read moreThe FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) trial assessed efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin in patients with knee osteoarthritis. Here, […]
» Read moreTo better understand the factors that influence the humoral immune response to vaccination against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs).Patients and controls from a large COVID-19 study, with […]
» Read moreThe objective of COAST-Y was to evaluate the effect of continuing versus withdrawing ixekizumab (IXE) in patients with axial spondyloarthritis (axSpA) who had achieved remission.COAST-Y is an ongoing, phase III, […]
» Read moreSeveral lines of evidence point towards the central role of interleukin 23 (IL-23) as a crucial inflammatory mediator in the pathogenesis of spondyloarthritis-a group of inflammatory arthritic diseases whose symptoms […]
» Read moreTo report the 10-year outcome of an inception cohort of patients with early rheumatoid arthritis (RA), the ESPOIR cohort, and predictors of outcome.From 2003 to 2005, 813 patients were included […]
» Read moreTo investigate survival of interleukin (IL)-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective.Multicentre retrospective […]
» Read moreTo compare the benefits of a tight-control/treat-to-target strategy (TC/T2T) in axial spondyloarthritis (axSpA) with those of usual care (UC).Pragmatic, prospective, cluster-randomised, controlled, open, 1-year trial (NCT03043846). 18 centres were randomised […]
» Read moreTo evaluate dose-response, efficacy and safety of dapirolizumab pegol (DZP) in patients with systemic lupus erythematosus (SLE).Adults with moderately to severely active SLE (SLEDAI-2K score ≥6 and ≥1 BILAG A […]
» Read moreTo date, there is almost no information concerning the sexual health of patients with idiopathic inflammatory myopathies (IIM). This cross-sectional study aimed to compare sexual function in patients with IIM […]
» Read moreCase reports and small case series suggest that stenotic lesions of the renal, coeliac and mesenteric arteries may occur in the antiphospholipid syndrome (APS) resulting in clinical consequences such as […]
» Read morePrimary non-response and secondary loss of response remain a significant issue with the currently available treatment options for a significant proportion of patients with inflammatory bowel disease (IBD). There are […]
» Read moreAs our understanding of the pathogenesis of SpA improves, focus has turned to the role janus kinase (JAK)-mediated signal transduction and inhibiting its actions as a therapeutic mechanism. Small molecule […]
» Read moreSeveral cytokines involved in inflammatory pathologies signal via the Janus kinase-signal transducer and activator of transcription pathway. Four JAKs are known: JAK1, JAK2, JAK3 and TYK2. The specific activation of […]
» Read moreUpadacitinib and filgotinib, two JAK1 selective drugs have undergone extensive phase III clinical trials in RA and have demonstrated rapid improvements in disease activity, function and patient reported outcomes. Six […]
» Read moreSystemic lupus erythematosus (SLE) can affect any part of the gastrointestinal (GI) tract. GI symptoms are reported to occur in more than 50% of SLE patients.To describe the GI manifestations […]
» Read moreAs efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other […]
» Read moreThe uptake of Jak inhibitors in the RA space has been among the most rapid in rheumatology, based on the results of comprehensive clinical trial programmes of five agents. Newer […]
» Read moreThe first approved Janus kinase (JAK) inhibitors for treatment of RA targeted more than one JAK molecule. Although this brings an advantage of simultaneous blocking of more cytokines involved in […]
» Read moreTakayasu arteritis (TAK), is a rare autoimmune rheumatic disease causing large vessel vasculitis. Onset is typically between the ages of 20-30. It is associated with substantial morbidity and mortality, notably […]
» Read moreProactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to standard therapy to maximize efficacy […]
» Read moreTo determine whether concomitant hydroxychloroquine modulates the increase in erythrocyte mean corpuscular volume (MCV) caused by methotrexate therapy, and whether this is associated with improved clinical response in rheumatoid arthritis […]
» Read moreCutaneous polyarteritis nodosa (CPAN) is a necrotizing vasculitis of the middle-size vessels, confined to the skin. We conducted a systematic review in order to identify studies evaluating the different treatment […]
» Read moreSustained remission has become an achievable goal for patients with rheumatoid arthritis (RA) receiving conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), but how to best treat patients in clinical remission remains […]
» Read moreSystemic sclerosis (SSc) results in impaired function, disability, and reduced health-related quality of life (HRQL). We investigated the impact of coping strategies on the patient global assessment of health (PtGA) […]
» Read moreEvaluate safety of guselkumab (monoclonal antibody targeting IL-23p19) in psoriatic arthritis (PsA) patients through 1year (1Y) of the Phase-3 DISCOVER-1&2 trials.Patients with active PsA (N=1120; biologic-naïve except the118 TNFi-treated DISCOVER-1 […]
» Read moreTocilizumab (TCZ) had similar efficacy when used as monotherapy or in combination with other treatments for rheumatoid arthritis (RA) in randomized controlled trials (RCT). We derived a remission prediction score […]
» Read more